Therapeutic trials have demonstrated that antidiabetic drugs such as liraglutide, pioglitazone, metformin, and a glucagon-like peptide 1 (GLP-1) might help to reduce hepatic steatosis [89,90,91] and liver fibrosis [89,90,92,93], while reducing NAFLD [94]. This evidence concerns the gene GCG and fatty liver disease.